Phaseline

Targets › PROTEASE

PROTEASE: drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 2; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on PROTEASE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesATV/co
HIV protease inhibitor boosted by cobicistat
PROTEASEPhase 2Acquired Immune Deficiency Syndrome (AIDS)Mar 2027
Gilead SciencesDRV/co
HIV protease inhibitor boosted by cobicistat
PROTEASEPhase 2Acquired Immune Deficiency Syndrome (AIDS)Mar 2027

Conditions

Acquired Immune Deficiency Syndrome (AIDS) (2)

Modalities

small molecule (2)

Companies

Gilead Sciences (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.